Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.
Also called NCT05410860
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 500 participants
- Registry
-
NCT05410860
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05410860. Randomized; triple masking; primary purpose treatment. Start 2022-06-30 (actual); primary completion 2024-08-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
- Condition
- Tachycardia, Supraventricular
- Condition
- Paroxysmal Supraventricular Tachycardia
- Intervention (Drug)
- Etripamil NS 70 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Corxel Pharmaceuticals
- Collaborator
- Milestone Pharmaceuticals Inc.
Record details
- Record id
cardio:ct-nct05410860- Content hash
59ba39b70df69698d3686afa959940aefd128935399e82115df76988c42b530b